Department of Oncology-Pathology
The Department of Oncology-Pathology conducts basic, translational and clinical research and educational activities related to cancer.
Lars Holmgren on twitter
Follow the chair of the department of Oncology-Pathology Lars Holmgren on twitter.
Svetlana Bajalica Lagercrantz new adjunct professor
Svetlana Bajalica Lagercrantz has been appointed as adjunct professor in cancer genetics at the department of Oncology-Pathology from 1st of June 2023.
New study regarding adjuvant therapy for melanoma
Hildur Helgadottir with colleagues in Gothenburg, Uppsala, Linköping, and Lund has published a new study in Journal of the National Cancer Institute. It shows that adjuvant therapy in an early stage of melanoma doesn´t give a positive effect on overall survival among Swedish patients.
Perspective article in Nature Reviews Cancer by Charlotte Rolny, Margarita Bartish and Ola Larsson
Associate Professor Charlotte Rolny, Associate Professor Ola Larsson and PhD Margarita Bartish has published a Perspective article in Nature Reviews Cancer dealing with mRNA translation in tumor-supporting cells of the tumor microenvironment.
Optimal treatment for breast cancer
Andri Papakonstantinou, Alexios Matikas and colleagues from Vall d'Hebron Institute of Oncology and Biomedical Institute August Pi i Sunye in Barcelona have published en network meta-analysis of 11000 patients in European Journal of Cancer that studies neoadjuvant therapy for HER2-positive breast cancer. Dual HER2 blockade plus chemotherapy without anthracycline is the optimal treatment at this setting. In addition, pathologic complete response is confirmed to be a poor surrogate of patient survival.
Andri Papakonstantinou becomes member of ESMO Public Policy Committee
Dr Andri Papakonstantinou, MD, PhD and manager of the breast cancer care within Karolinska Comprehensive Cancer Centre has been appointed member of the European Society for Medical Oncology (ESMO) Public Policy Committee (PPC). ESMO PPC’s mission is to advocate for sustainable cancer care worldwide. ESMO PPC collaborates with among others WHO and UN to shape global, regional, and national health policies.
Funding from The Swedish Cancer Society to OnkPat 2023
In this year’s announcement of research funding from the Swedish Cancer Society, Fredrik Strand has been awarded Junior Clinical Investigator Award of 7 296 000 SEK, Christofer Juhlin has been awarded Senior Clinical Investigator Award of 5 214 000 SEK, and the research school NatiOn, Nationell forskarskola I klinisk och translationell cancerforskning has been awarded 2 400 000 SEK.
Life-threatening side effects of novel cancer immunotherapies could be treatable
Immunotherapy has been shown to greatly improve survival rates for certain types of cancer. However, in some cases, it can lead to an over-activation of the immune system, which can be dangerous. In a recent review by Lisa Liu and Marcus Skribek at the department of Oncology-Pathology together with colleagues, potential therapies have been identified, which might make it possible to continue with immunotherapy even when facing severe side effects. The study is published in Journal for ImmunoTherapy of Cancer.